Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in RLAY.
← Back to Free Index

RLAY

Analysis as of: 2026-06-14
Relay Therapeutics, Inc.
Clinical-stage biotechnology company developing small-molecule therapies for cancer and genetic disease using a computational and experimental drug-discovery engine.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Pivotal Proof, Bigger Runway, Still One Franchise
One asset can plausibly become a real multi-indication franchise, and the balance sheet now gives management time to prove it. The upside is meaningful, but nearly all of it still runs through a small number of zovegalisib clinical and regulatory gates.

Analysis

Thesis
Relay is a concentrated franchise bet: if zovegalisib confirms a cleaner PI3Kα profile in Phase 3 and opens vascular anomalies plus frontline breast cancer, the company can turn its stronger balance sheet into a real multi-indication revenue engine by 2031; if not, the platform alone will not carry valuation.
Last Economy Alignment
AI helps Relay design candidates faster and improve its internal data loop, but value capture still sits in owned drug IP, clinical outcomes and regulatory trust rather than software packaging. That makes Relay moderately helped by cheaper cognition, not transformed by it.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.7x (from 5 most recent analyses)
Reasoning
The upside comes from Relay changing category in investors’ minds—from a clinical option on one program to a credible precision-medicine franchise with two meaningful use cases and some ex-U.S. monetization. The recent financing removes near-term survival risk, so the next value step is proof, not cash access. I still keep the multiple below best-in-class diversified peers because value is highly concentrated in zovegalisib and the platform has not yet shown repeated late-stage conversion.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
Relay’s main risk is concentrated proof, not financing or software disruption. The balance sheet is much better after the May raise, but the equity still depends on zovegalisib holding a differentiated safety and tolerability profile through later-stage data, winning a workable frontline FDA path, and converting that proof into durable prescribing behavior before dilution or competition erodes the prize.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.32
They own the drug rights and a data loop that can help design better medicines faster, so AI can improve their odds. But computers do not remove the hard part: proving the drug works safely in patients and getting regulators to agree.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$24.25
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case